Skip to main content
. 2023 Dec 14;10(1):e23699. doi: 10.1016/j.heliyon.2023.e23699

Fig. 1.

Fig. 1

Timelines showing patient disease course, therapies and vaccinations, and results from assessment of antibody-based immune responses to SARS-CoV-2. (A) Immunocompromised patient's clinical course of COVID-19. Maize and purple markers denote SARS-CoV-2 test results. Green denotes a positive viral culture. Downward markers note medical events. (B) Immunotherapies & vaccinations. IVIG (500 mg), convalescent plasma treatment (unknown titer), and vaccination events are shown on the same timescale as A. (C) SARS-CoV-2 IgG assay results. Red markers indicate negative IgG test, green indicate positive IgG test. All IgG tests performed between November 6, 2020, and March 2, 2021, were done using the Abbott ARCHITECT SARS-CoV-2 IgG assay, which detects antibodies directed to a recombinant Nucleocapsid (N) SARS-CoV-2 antigen. IgG tests performed after March 2, 2021, were done using the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy), which detects IgG antibodies to the spike (S) protein. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)